可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease[J]. Pharmacol Ther, 2009,122(3):246-263.
[2]Stienstra R, Duval C, Muller M, et al. PPARs, Obesity, and Inflammation[J]. PPAR Res, 2007, 2007:95974.
[3]Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature[J]. Circulation, 1979, 59(3):607-609.
[4]Ross R. Atherosclerosis--an inflammatory disease[J]. N Engl J Med, 1999, 340(2):115-126.
[5]宋涛,冯莉萍,夏豪,等. 粥样斑块发生发展过程中炎症和新生内膜血管之间的关系[J]. 心脏杂志, 2006, 18(6):636-642.
[6]李凝旭. 核因子-κB、炎症与急性冠状动脉综合征[J]. 心脏杂志, 2002, 14(1):66-68.
[7 ]Rus H, Niculescu F. Inflammatory response in unstable angina[J]. Circulation, 1999, 100(19):e98.
[8]Ikeda U, Ito T, Shimada K. Interleukin-6 and acute coronary syndrome[J]. Clin Cardiol, 2001, 24(11):701-704.
[9]Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease[J]. Heart, 1997, 78(3):273-277.
[10]Smith DA, Irving SD, Sheldon J, et al. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina[J]. Circulation, 2001, 104(7):746-749.
[11]Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes[J]. Circulation, 2003, 107(16):2109-2114.
[12]Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation[J]. Inflamm Res, 2000, 49(10):497-505.
[13]Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives[J]. Cell Mol Life Sci, 2002, 59(5):790-798.
[14]Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors[J]. Endocrinology, 2003, 144(6):2201-2207.
[15]Graham TL, Mookherjee C, Suckling KE, et al. The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice[J]. Atherosclerosis, 2005, 181(1):29-37.
[16]Barish GD, Atkins AR, Downes M, et al. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis[J]. Proc Natl Acad Sci U S A, 2008, 105(11):4271-4276.